STOCK TITAN
  1. Home
  2. Sec-filings
  3. PPBT
  4. [Form 3] PURPLE BIOTECH LTD. Initial Statement of Beneficial Ownership

Purple Biotech (PPBT) executive reports 9.25M shares plus multi-year options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

PURPLE BIOTECH LTD. executive Michael Schickler filed an initial ownership report showing 9,254,472 Ordinary Shares, including 6,958,334 unvested restricted stock units that vest over time and settle in Ordinary Shares. He also holds several stock options over Ordinary Shares with exercise prices between $0.10828125 and $0.00309375 per share, expiring between April 2027 and October 2030, some already vested and others vesting in quarterly installments.

Positive

  • None.

Negative

  • None.
Insider Schickler Michael
Role Head of Clinical & Reg Affairs
Type Security Shares Price Value
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Stock Option (Right to Buy) -- -- --
holding Ordinary Shares -- -- --
Holdings After Transaction: Stock Option (Right to Buy) — 151,000 shares (Direct); Ordinary Shares — 9,254,472 shares (Direct)
Footnotes (1)
  1. Includes 6,958,334 unvested restricted stock units ("RSUs"), each with respect to one ordinary share, no par value, per share ("Ordinary Shares"), of Purple Biotech Ltd. (the "Issuer"). The RSUs are subject to time-based vesting conditions and are settled in Ordinary Shares. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares Represents stock option to purchase 151,000 Ordinary Shares (equivalent to 76 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. The Ordinary Shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $0.10828125 per Ordinary Share and the option expires on April 2, 2027. Represents stock option to purchase 900,000 Ordinary Shares (equivalent to 450 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $0.095054688 per Ordinary Share and the option expires on May 23, 2027. Represents stock option to purchase 900,000 Ordinary Shares (equivalent to 450 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. Options to purchase 393,750 Ordinary Shares are vested and exercisable, with the remaining options to purchase 506,250 Ordinary Shares vesting in equal quarterly installments until August 14, 2027.The exercise price of this stock option is $0.0115625 per Ordinary Share and the option expires on August 15, 2029. Represents stock option to purchase 7,100,000 Ordinary Shares (equivalent to 3,550 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. Options to purchase 591,666 Ordinary Shares are vested and exercisable, with the remaining options to purchase 6,508,334 Ordinary Shares vesting in equal quarterly installments until October 21, 2028.The exercise price of this stock option is $0.00309375 per Ordinary Share and the option expires on October 21, 2030
Ordinary Shares held 9,254,472 Ordinary Shares Total beneficial ownership reported on Form 3
Unvested RSUs 6,958,334 RSUs Each RSU for one Ordinary Share, time-based vesting
ADS ratio 2,000 Ordinary Shares per ADS Ordinary Shares may be represented by ADSs
Option grant 1 151,000 shares at $0.10828125 Exercise price per Ordinary Share, expires April 2, 2027
Option grant 2 900,000 shares at $0.095054688 Exercise price per Ordinary Share, expires May 23, 2027
Option grant 3 vesting 393,750 vested / 506,250 unvested of 900,000 Vests quarterly until August 14, 2027 at $0.0115625, expires August 15, 2029
Option grant 4 vesting 591,666 vested / 6,508,334 unvested of 7,100,000 Vests quarterly until October 21, 2028 at $0.00309375, expires October 21, 2030
restricted stock units ("RSUs") financial
"Includes 6,958,334 unvested restricted stock units ("RSUs"), each with respect to one ordinary share"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
American Depositary Shares financial
"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares"
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
exercise price financial
"The exercise price of this stock option is $0.10828125 per Ordinary Share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting in equal quarterly installments financial
"remaining options to purchase 506,250 Ordinary Shares vesting in equal quarterly installments until August 14, 2027"
Equity-Based Incentive Plan financial
"issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan"
Understanding Insider Trading Forms →
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Schickler Michael
(Last)(First)(Middle)
4 OPPENHEIMER STREET
SCIENCE PARK
(Street)
REHOVOT7670104
(City)(State)(Zip)
ISRAEL
(Country)		2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026		3. Issuer Name and Ticker or Trading Symbol
PURPLE BIOTECH LTD. [ PPBT ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Head of Clinical & Reg Affairs
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares9,254,472(1)D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy) (2) (2)Ordinary Shares151,000(2)D
Stock Option (Right to Buy) (3) (3)Ordinary Shares900,000(3)D
Stock Option (Right to Buy) (4) (4)Ordinary Shares900,000(4)D
Stock Option (Right to Buy) (5) (5)Ordinary Shares7,100,000(5)D
Explanation of Responses:
1. Includes 6,958,334 unvested restricted stock units ("RSUs"), each with respect to one ordinary share, no par value, per share ("Ordinary Shares"), of Purple Biotech Ltd. (the "Issuer"). The RSUs are subject to time-based vesting conditions and are settled in Ordinary Shares. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares
2. Represents stock option to purchase 151,000 Ordinary Shares (equivalent to 76 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. The Ordinary Shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $0.10828125 per Ordinary Share and the option expires on April 2, 2027.
3. Represents stock option to purchase 900,000 Ordinary Shares (equivalent to 450 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $0.095054688 per Ordinary Share and the option expires on May 23, 2027.
4. Represents stock option to purchase 900,000 Ordinary Shares (equivalent to 450 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. Options to purchase 393,750 Ordinary Shares are vested and exercisable, with the remaining options to purchase 506,250 Ordinary Shares vesting in equal quarterly installments until August 14, 2027.The exercise price of this stock option is $0.0115625 per Ordinary Share and the option expires on August 15, 2029.
5. Represents stock option to purchase 7,100,000 Ordinary Shares (equivalent to 3,550 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. Options to purchase 591,666 Ordinary Shares are vested and exercisable, with the remaining options to purchase 6,508,334 Ordinary Shares vesting in equal quarterly installments until October 21, 2028.The exercise price of this stock option is $0.00309375 per Ordinary Share and the option expires on October 21, 2030
/s/ Michael Schickler03/30/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What does Michael Schickler report owning in Purple Biotech (PPBT)?

He reports beneficial ownership of 9,254,472 Ordinary Shares of Purple Biotech. This figure includes both already-issued shares and a large block of unvested RSUs that will settle in Ordinary Shares as time-based vesting conditions are met.

How many unvested RSUs does the Purple Biotech (PPBT) executive hold?

He holds 6,958,334 unvested restricted stock units (RSUs), each representing one Ordinary Share. These RSUs vest over time based on service conditions and are settled in Ordinary Shares, which may be represented by American Depositary Shares.

What stock options over Purple Biotech (PPBT) shares does Schickler have?

He has options to purchase 151,000, 900,000, another 900,000, and 7,100,000 Ordinary Shares at exercise prices between $0.10828125 and $0.00309375 per share. These options were granted under the company’s 2016 Equity-Based Incentive Plan.

When do Michael Schickler’s Purple Biotech (PPBT) stock options expire?

His reported stock options expire on April 2, 2027, May 23, 2027, August 15, 2029, and October 21, 2030. These expirations apply to different option grants, each with its own exercise price and vesting schedule.

How much of Schickler’s 7,100,000-share Purple Biotech (PPBT) option is vested?

Out of the 7,100,000 Ordinary Shares covered by that option, 591,666 are vested and exercisable. The remaining 6,508,334 shares vest in equal quarterly installments until October 21, 2028, subject to continued service.

What is the ADS ratio for Purple Biotech (PPBT) in this filing?

Each American Depositary Share (ADS) currently represents 2,000 Ordinary Shares of Purple Biotech. This means the equity awards and holdings reported in Ordinary Shares could also be represented in ADS form using that 2,000-to-1 ratio.